Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.67 |
| ▸ | DRD5 | P21918 | 4/20 | 0.67 |
| ▸ | DRD4 | P21917 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110986 | 0.89 | DRD1 (0.71) | DRD1DRD5DRD4KDM4EPOLB | |
| SCHEMBL6997049 | 0.84 | DRD1 (0.72) | DRD1DRD5DRD4KDM4EPOLB | |
| SCHEMBL6935354 | 0.83 | DRD1 (0.71) | DRD1DRD5DRD4KDM4EPOLB | |
| SCHEMBL7123326 | 0.83 | DRD1 (0.71) | DRD1DRD5DRD4KDM4EPOLB | |
| SCHEMBL240294 | 0.83 | DRD1 (0.71) | DRD1DRD5DRD4KDM4EPOLB | |
| SCHEMBL8703127 | 0.83 | DRD1 (0.74) | DRD1DRD5DRD4KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL7114617 | 0.82 | DRD1 (0.69) | DRD1DRD5DRD4KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL14966707 | 0.82 | DRD1 (0.69) | DRD1DRD5DRD4KDM4EPOLB | |
| SCHEMBL8796222 | 0.82 | KDM4E (0.66) | DRD1DRD5DRD4KDM4EDRD3 | |
| Hydrochloric Acid SCHEMBL8703895 | 0.82 | DRD1 (0.73) | DRD1DRD5DRD4KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | DRD1 3691/4885DRD5 2435/4885DRD4 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.